Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?

Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer is an aggressive phenotype with a poor prognosis, and can easily metastasize and recur. Currently, chemotherapy plus HER2-targeted therapy is the standard systemic treatment for most of these patients. Given that neoadjuvan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chin J Cancer Res
Autors principals: Wu, Juan, Kong, Rong, Tian, Shen, Li, Hao, Wu, Kainan, Kong, Lingquan
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6955160/
https://ncbi.nlm.nih.gov/pubmed/31949390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2019.06.04
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars